Yang Hu

Postdoktor vid Institutionen för farmaci, Translationell PKPD

E-post:
yang.hu[AT-tecken]farmbio.uu.se
Besöksadress:
Biomedicinskt Centrum BMC, Husargatan 3
752 37 Uppsala
Postadress:
Box 580
751 23 UPPSALA

Postdoktor vid Institutionen för farmaci, Translationell PKPD

E-post:
yang.hu[AT-tecken]farmaci.uu.se
Besöksadress:
Biomedicinskt Centrum BMC, Husargatan 3
752 37 Uppsala
Postadress:
Box 580
751 23 UPPSALA

Kort presentation

I am currently a postdoctoral fellow in Translational PKPD research group with strong research interests in neuropharmacokinetics, blood-brain barrier, neurotoxicity, brain drug delivery, nanocarrier delivery systems

Nyckelord: in vivo neurotoxicity pharmacokinetics blood brain barrier microdialysis brain drug delivery nanocarriers transporters

Detta stycke finns inte på svenska, därför visas den engelska versionen.

My current project focuses on investigating the pharmacokinetic aspects of the development of drug-induced neurotoxicity, as a part of EU-IMI2 project NeuroDeRisk (Neurotoxicity derisking in preclinical drug discovery).

Neurotoxicity, ie any adverse effect on the central nervous system or peripheral nervous system, is a major issue encountered in clinical phases of drug R&D that at the present stage of science and technology is still poorly predicted in the pre-clinical drug candidate assessment. As part of the EU IMI2-RIA funded consortium NeuroDeRisk (Neurotoxicity De-Risking in Preclinical Drug Discovery) will provide novel validated and integrated tools to improve the preclinical prediction of adverse effects of pharmaceuticals on the nervous system, thus helping to de-risk drug candidates earlier in the R&D phases. Together with EFPIA members Sanofi, Novartis, MSD, Pfizer, UCB, Biopharma, AZ, Fujifilm Cellular Dynamics and a group of leading EU academic institutions,

For more details visit the web page: http://neuroderisk.eu/

Kontakta katalogansvarig vid den aktuella organisationen (institution eller motsv.) för att rätta ev. felaktigheter.

Yang Hu